Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) have received a consensus rating of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $4.25.

Several brokerages have recently issued reports on MRSN. Wedbush reiterated an “outperform” rating and issued a $4.00 price objective on shares of Mersana Therapeutics in a research note on Monday, March 3rd. William Blair began coverage on Mersana Therapeutics in a research note on Thursday, February 6th. They issued an “outperform” rating on the stock.

Institutional Trading of Mersana Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Los Angeles Capital Management LLC raised its stake in Mersana Therapeutics by 8.1% in the third quarter. Los Angeles Capital Management LLC now owns 189,660 shares of the company’s stock valued at $358,000 after buying an additional 14,240 shares in the last quarter. US Bancorp DE acquired a new stake in Mersana Therapeutics in the third quarter valued at $31,000. Dynamic Technology Lab Private Ltd acquired a new stake in Mersana Therapeutics in the third quarter valued at $34,000. Wells Fargo & Company MN raised its stake in Mersana Therapeutics by 40.3% in the fourth quarter. Wells Fargo & Company MN now owns 67,483 shares of the company’s stock valued at $97,000 after buying an additional 19,368 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in Mersana Therapeutics by 28.7% in the fourth quarter. SG Americas Securities LLC now owns 112,291 shares of the company’s stock valued at $161,000 after buying an additional 25,058 shares in the last quarter. 93.92% of the stock is currently owned by institutional investors and hedge funds.

Mersana Therapeutics Trading Up 3.0 %

MRSN opened at $0.48 on Thursday. Mersana Therapeutics has a 52 week low of $0.44 and a 52 week high of $5.11. The business has a fifty day simple moving average of $0.62 and a 200-day simple moving average of $1.49. The firm has a market cap of $59.70 million, a P/E ratio of -0.79 and a beta of 1.67. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 13.35.

Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. The business had revenue of $16.36 million for the quarter, compared to analysts’ expectations of $7.71 million. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. On average, equities analysts expect that Mersana Therapeutics will post -0.62 earnings per share for the current year.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.